SF3712
Standards for utilization review performance modifications
Legislative Session 94 (2025-2026)
Related bill: HF3867
AI Generated Summary
Purpose
This bill would modify how utilization review organizations (UROs) handle prior authorization decisions, require more transparency and timely communication, establish potential penalties for excessive overturned determinations, and create new avenues for enrollees to seek relief when a prior authorization denial harms them. It also adds enforcement and oversight provisions involving state agencies and licensing boards.
Key Provisions (What the bill would change or add)
Information requests when there’s disagreement
- If there is significant lack of agreement between a URO and a provider about whether a service should be authorized, the URO may request additional information.
- Before issuing an adverse (denial) determination, a reviewing physician must contact the attending health care professional to obtain more details on medical necessity.
- UROs may require data needed to comply with quality assurance and utilization review requirements.
Standard review determinations and notification timelines
- All standard determinations must be communicated to the provider and enrollee within five business days after the request is received, provided all necessary information is available.
- If a decision is to authorize, the provider must be notified promptly by telephone; written notification and an audit trail must be maintained (including who was contacted, the service, and dates).
- Adverse determinations must be communicated with specific notification methods (telephone, fax, or secure email) and include the reasons relied on and how to appeal.
- The URO must, upon request, share the criteria used to determine necessity, appropriateness, and efficacy of the service.
- Reasons for an adverse determination may include lack of adequate information after reasonable contact attempts.
Oversight, fines, and enforcement
- The commissioner of commerce would be able to impose fines on a URO if the rate at which adverse determinations are reversed exceeds 40% over any 12-month period, for expedited, standard, or external reviews.
- The bill sets a cap on fines (though the exact amount is not shown in the provided text).
Retrospective revocation or limitation of prior authorization
- A prior authorization cannot be revoked or limited after it is granted unless there is evidence of fraud, misinformation, or conflicts with state or federal law.
- Applies that applying a deductible, coinsurance, or other cost-sharing does not count as a limit or restriction.
New cause of action for enrollees (civil remedies)
- Enrollees injured by a denial of prior authorization may sue the URO if:
- An adverse determination deviates from accepted medical norms and the attending health care professional’s recommendation.
- The adverse determination causes injury to the enrollee.
- The plaintiff must show the URO disregarded the attending professional judgment and relevant information supporting the initial request or appeal.
- If successful, damages can include general and special damages (including mental anguish), punitive damages, injunctive relief, and attorneys’ fees.
- Administrative complaint option: enrollees may file a complaint with the state regulator before, during, or after a civil action.
- Immunity: attending health care professionals are immune from civil liability under this provision.
Significant Changes to Existing Law (What changes)
- Adds duties for UROs to seek additional information and to contact attending physicians before adverse determinations.
- Requires standardized, timely communications and detailed audit trails for determinations.
- Introduces a fines mechanism for high reversal rates of determinations, with a cap (amount not specified in excerpt).
- Prohibits retrospective reversal/limitation of prior authorizations except in cases of fraud, misinformation, or legal conflict.
- Creates a new private right of action and related remedies for enrollees harmed by denial decisions, and provides for regulatory complaints and physician immunity.
Practical Implications for Stakeholders
- Enrollees may have clearer timelines, more information about why a denial occurred, and a direct pathway to appeal or sue if harmed.
- Providers could face tighter requirements for information gathering and documentation to support authorizations.
- UROs face potential penalties if their denial reversal rate is high and must improve processes to justify medical necessity and adherence to norms.
- State enforcement bodies (Commissioner of Commerce and health-related licensing boards) gain new oversight and enforcement tools.
Implementation Notes
- The text provided does not specify an effective date; details may appear in the full bill or final version.
- The bill references external review under existing law (section 62Q.73) and quality assurance/data requirements under chapter 62D.
Important Definitions (key terms used in or affected by the bill)
- Utilization review organization (URO)
- Prior authorization
- Adverse determination
- Standard review determination
- Expedited appeals
- External reviews
- Medical necessity
- Attending health care professional
- Enrollee
- Audit trail
- Authorization number
- Health-related licensing boards
- Commissioner of commerce
- Attorney general enforcement
- Quality assurance and utilization review requirements (chapter 62D)
Potential Areas of Impact
- Patient experience: more timely, transparent decisions and clearer avenues for challenge.
- Medical practice: heightened documentation and coordination between providers and UROs.
- Legal environment: new civil liability pathway for enrollees and regulatory penalties for UROs.
Relevant Terms utilization review organization; prior authorization; adverse determination; medical necessity; standard review; expedited appeals; external reviews; audit trail; authorization number; attending health care professional; enrollee; commissioner of commerce; health-related licensing boards; attorney general enforcement; quality assurance; utilization review requirements; data; treatment parameters; substantiation; retroactive revocation; fraud; misinformation; punitive damages; injunctive relief; immunit y.
Actions
| Date | Chamber | Where | Type | Name | Committee Name |
|---|---|---|---|---|---|
| February 19, 2026 | Senate | Action | Introduction and first reading | ||
| February 19, 2026 | Senate | Action | Referred to | Commerce and Consumer Protection | |
| February 23, 2026 | Senate | Action | Author added | ||
| Showing the 5 most recent stages. This bill has 3 stages in total. Log in to view all stages | |||||
Citations
You must be logged in to view citations.
Progress through the legislative process
Sponsors
You must be logged in to view sponsors.